Compass Therapeutics Inc Stock Price, News & Analysis

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the H.C. Wainwright BioConnect Investor Conference in New York City on May 2, 2023. The event will feature a Fireside Chat scheduled for 10 AM ET. A webcast link for the presentation is available online. Following the live event, a replay will be archived for 90 days on Compass's Events page. Compass Therapeutics is focused on developing proprietary antibody-based therapeutics targeting oncology, aiming to engage multiple critical biological pathways for effective anti-tumor responses. Founded in 2014 and based in Boston, the company is dedicated to advancing its clinical pipeline with novel product candidates.

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25 – 26, 2023. The company will engage in a fireside chat on April 26 at 11 AM ET, which can be accessed via a webcast. The corporate presentation will be archived for 90 days on their Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics aimed at treating various human diseases. Central to their research is the relationship between angiogenesis, the immune system, and tumor growth. Their innovative pipeline targets critical biological pathways to enhance anti-tumor responses. For further details, visit www.compasstherapeutics.com.

Compass Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the Cantor Fitzgerald Future of Oncology Symposium scheduled for April 3-5, 2023. The company will present on April 4 at 8:15 AM ET. Compass Therapeutics is developing proprietary antibody-based therapeutics targeting various human diseases, emphasizing the interplay between angiogenesis, the immune system, and tumor growth. Their innovative pipeline aims to address critical biological pathways for effective anti-tumor responses, advancing both standalone therapies and combination strategies. Founded in 2014, the company is headquartered in Boston, Massachusetts.

Compass Therapeutics (CMPX) announced several advancements in its clinical pipeline, including the initiation of U.S. Phase 2/3 trials for CTX-009 targeting advanced biliary tract cancers (BTC) and colorectal cancer (CRC). The company presented promising Phase 2 results at the 2023 ASCO GI Cancers Symposium, reporting a 37.5% overall response rate (ORR) in BTC patients. Financially, Compass ended 2022 with $187 million in cash, ensuring a runway until 2026. The net loss for the year was $39.2 million, a reduction from $82.2 million in 2021 due to decreased non-recurrent R&D expenses. Initial results from current trials are expected in 2023 and 2024.

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. A significant event will be the fireside chat on February 15 at 11:20 AM ET, accessible via a live webcast. Investors can view the archived presentation for 90 days on the Company’s Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology and aims to advance its products through clinical development, addressing critical biological pathways for effective anti-tumor responses.

Compass Therapeutics, Inc. (Nasdaq: CMPX) announced promising data from a Phase 2 study of CTX-009 combined with paclitaxel for biliary tract cancers (BTC). The study revealed a 37.5% overall response rate (ORR) across all 24 patients, with a notable 63.6% ORR in the second-line subgroup. Median progression-free survival (PFS) was 9.4 months and overall survival (OS) was 12.5 months. Safety profiles were consistent with prior studies, as 95.8% of patients experienced grade 3 or higher treatment-emergent adverse events. A randomized Phase 2/3 trial of CTX-009 in the U.S. has been initiated, potentially supporting a biologics license application in 2024.

Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced the dosing of the first patient in a Phase 2 clinical study of CTX-009 for metastatic colorectal cancer. This study targets patients who have undergone at least two previous therapies and will evaluate safety and clinical response. The drug is designed to block critical cancer pathways, with prior Phase 1 studies showing confirmed responses. Preliminary results are expected mid-2023, marking a significant development in treatment options for patients facing limited therapies.